Skip to main content
PMC home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1980 Apr;9(4):399–405. doi: 10.1111/j.1365-2125.1980.tb01068.x

Roles of hepatic blood flow and enzyme activity in the kinetics of propranolol and sotalol.

H I Pirttiaho, E A Sotaniemi, R O Pelkonen, U Pitkänen, M Anttila, H Sundqvist
PMCID: PMC1429970  PMID: 7378257

Abstract

1 The roles of the hepatic blood flow and the drug oxidizing enzyme system in eliminating oral propranolol and sotalol were studied in twelve subjects with biopsy proven liver parenchymal disease. 2 The apparent plasma clearance of propranolol was closely related both to the in vivo (antipyrine test) and in vitro (cytochrome P-450) indices of the activity of the hepatic mixed function oxidase system. 3 Propranolol clearance had also a clear relationship to the estimated liver blood flow. Altered flow was, however, suggested to be a minor factor when compared with changes in the enzyme system. 4 The elimination rate of sotalol had no correlation to the indices of hepatic drug metabolism or to the estimated liver blood flow. 5 It is concluded that both the deteriorated sinusoidal perfusion and the decreased mass of drug metabolizing enzymes may be responsible for the impaired elimination of oral propranolol in subjects with parenchymal liver disease.

Full text

PDF
404

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anttila M., Arstila M., Pfeffer M., Tikkanen R., Vallinkoski V., Sundquist H. Human pharmacokinetics of sotalol. Acta Pharmacol Toxicol (Copenh) 1976 Jul;39(1):118–128. doi: 10.1111/j.1600-0773.1976.tb03162.x. [DOI] [PubMed] [Google Scholar]
  2. Branch R. A., Shand D. G. Propranolol disposition in chronic liver disease: a physiological approach. Clin Pharmacokinet. 1976;1(4):264–279. doi: 10.2165/00003088-197601040-00002. [DOI] [PubMed] [Google Scholar]
  3. Garrett E. R., Schnelle K. Separation and spectrofluorometric assay of the -adrenergic blocker sotalol from blood and urine. J Pharm Sci. 1971 Jun;60(6):833–839. doi: 10.1002/jps.2600600607. [DOI] [PubMed] [Google Scholar]
  4. Greim H., Schenkman J. B., Klotzbücher M., Remmer H. The influence of phenobarbital on the turnover of hepatic microsomal cytochrome b5 and cytochrome P-450 hemes in the rat. Biochim Biophys Acta. 1970 Jan 27;201(1):20–25. doi: 10.1016/0304-4165(70)90005-x. [DOI] [PubMed] [Google Scholar]
  5. Groszmann R. J., Kravetz D., Parysow O. Intrahepatic arteriovenous shunting in cirrhosis of the liver. Gastroenterology. 1977 Jul;73(1):201–204. [PubMed] [Google Scholar]
  6. Groszmann R., Kotelanski B., Cohn J. N., Khatri I. M. Quantitation of portasystemic shunting from the splenic and mesenteric beds in alcoholic liver disease. Am J Med. 1972 Dec;53(6):715–722. doi: 10.1016/0002-9343(72)90188-x. [DOI] [PubMed] [Google Scholar]
  7. Halliwell M., Homeida M., Roberts C. J. Value of liver volume measurement in the study of antipyrine kinetics in liver disease [proceedings]. Br J Clin Pharmacol. 1977 Jun;4(3):393P–394P. [PubMed] [Google Scholar]
  8. Kornhauser D. M., Wood A. J., Vestal R. E., Wilkinson G. R., Branch R. A., Shand D. G. Biological determinants of propranolol disposition in man. Clin Pharmacol Ther. 1978 Feb;23(2):165–174. doi: 10.1002/cpt1978232165. [DOI] [PubMed] [Google Scholar]
  9. Nies A. S., Shand D. G., Wilkinson G. R. Altered hepatic blood flow and drug disposition. Clin Pharmacokinet. 1976;1(2):135–155. doi: 10.2165/00003088-197601020-00005. [DOI] [PubMed] [Google Scholar]
  10. POPPER H., ELIAS H., PETTY D. E. Vascular pattern of the cirrhotic liver. Am J Clin Pathol. 1952 Aug;22(8):717–729. doi: 10.1093/ajcp/22.8.717. [DOI] [PubMed] [Google Scholar]
  11. Pessayre D., Lebrec D., Descatoire V., Peignoux M., Benhamou J. P. Mechanism for reduced drug clearance in patients with cirrhosis. Gastroenterology. 1978 Mar;74(3):566–571. [PubMed] [Google Scholar]
  12. Pirttiaho H. I., Pitkänen U. Size and blood flow of the liver estimated by 99Tcm scanning. Acta Radiol Ther Phys Biol. 1977 Dec;16(6):497–506. doi: 10.3109/02841867709133971. [DOI] [PubMed] [Google Scholar]
  13. Pirttiaho H. I., Sotaniemi E. A., Ahlqvist J., Pitkänen U., Pelkonen R. O. Liver size and indices of drug metabolism in alcoholics. Eur J Clin Pharmacol. 1978 Mar 17;13(1):61–67. doi: 10.1007/BF00606684. [DOI] [PubMed] [Google Scholar]
  14. Pirttiaho H. I., Sotaniemi E. A., Ahokas J. T., Pitkänen U. Liver size and indices of drug metabolism in epileptics. Br J Clin Pharmacol. 1978 Sep;6(3):273–278. doi: 10.1111/j.1365-2125.1978.tb04597.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Pirttiaho H. Liver size in evaluating drug metabolizing capacity in man. Int J Clin Pharmacol Biopharm. 1979 Jun;17(6):271–276. [PubMed] [Google Scholar]
  16. Preisig R., Bircher J., Paumgartner G. Physiologic and pathophysiologic aspects of the hepatic hemodynamics. Prog Liver Dis. 1972;4:201–216. [PubMed] [Google Scholar]
  17. Prescott L. F., Adjepon-Yamoah K. K., Roberts E. Rapid gas-liquid chromatographic estimation of antipyrine in plasma. J Pharm Pharmacol. 1973 Mar;25(3):205–207. doi: 10.1111/j.2042-7158.1973.tb10625.x. [DOI] [PubMed] [Google Scholar]
  18. Rollo F. D., DeLand F. H. The determination of liver mass from radionuclide images. Radiology. 1968 Dec;91(6):1191–1194. doi: 10.1148/91.6.1191. [DOI] [PubMed] [Google Scholar]
  19. Schoene B., Fleischmann R. A., Remmer H., von Oldershausen H. F. Determination of drug metabolizing enzymes in needle biopsies of human liver. Eur J Clin Pharmacol. 1972 Mar;4(2):65–73. doi: 10.1007/BF00562499. [DOI] [PubMed] [Google Scholar]
  20. Shand D. G., Kornhauser D. M., Wilkinson G. R. Effects of route of administration and blood flow on hepatic drug elimination. J Pharmacol Exp Ther. 1975 Dec;195(3):424–432. [PubMed] [Google Scholar]
  21. Shand D. G., Nuckolls E. M., Oates J. A. Plasma propranolol levels in adults with observations in four children. Clin Pharmacol Ther. 1970 Jan-Feb;11(1):112–120. doi: 10.1002/cpt1970111112. [DOI] [PubMed] [Google Scholar]
  22. Sotaniemi E. A., Ahlqvist J., Pelkonen R. O., Pirttiaho H., Luoma P. V. Histological changes in the liver and indices of drug metabolism in alcoholics. Eur J Clin Pharmacol. 1977 Apr 20;11(4):295–303. doi: 10.1007/BF00607680. [DOI] [PubMed] [Google Scholar]
  23. Sotaniemi E. A., Pelkonen R. O., Ahokas J., Pirttiaho H. I., Ahlqvist J. Drug metabolism in epileptics: in vivo and in vitro correlations. Br J Clin Pharmacol. 1978 Jan;5(1):71–76. doi: 10.1111/j.1365-2125.1978.tb01600.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Sundquist H., Anttila M., Arstila M. Antihypertensive effects of practolol and sotalol. Clin Pharmacol Ther. 1974 Sep;16(3):465–472. doi: 10.1002/cpt1974163part1465. [DOI] [PubMed] [Google Scholar]
  25. Wilkinson G. R., Schenker S. Effects of liver disease on drug disposition in man. Biochem Pharmacol. 1976 Dec 15;25(24):2675–2681. doi: 10.1016/0006-2952(76)90256-2. [DOI] [PubMed] [Google Scholar]
  26. Wilkinson G. R., Shand D. G. Commentary: a physiological approach to hepatic drug clearance. Clin Pharmacol Ther. 1975 Oct;18(4):377–390. doi: 10.1002/cpt1975184377. [DOI] [PubMed] [Google Scholar]
  27. Wood A. J., Kornhauser D. M., Wilkinson G. R., Shand D. G., Branch R. A. The influence of cirrhosis on steady-state blood concentrations of unbound propranolol after oral administration. Clin Pharmacokinet. 1978 Nov-Dec;3(6):478–487. doi: 10.2165/00003088-197803060-00005. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES